Abstract
We studied the effects of a premeal sc injection of an analog of somatostatin (SMS 201–995, Sandoz) on the postprandial glycemic excursions, insulin requirement and hormone profiles (GH, glucagon and C-peptide) in 8 IDDM patients (diabetes duration 14.0 ± 6.5 yr, daily insulin requirement 36 ± 6.4 U) maintained normoglycemic by connecting them to a closed-loop insulin infusion system (Betalike, Genoa). The morning of the test the patients were connected to the Betalike and their glucose levels stabilized for at least 4 h. At 13:00 h the study was begun with a sc injection of 50 μg of SMS 201–995 or placebo (randomly) and a standardized mixed meal (800 Kcal) was given. Blood samples were obtained 0, 15, 30, 60, 120 and 180 min after the injection. Each patient was tested both with SMS 201–995 and placebo. Postmeal glycemic peaks were decreased after SMS 201–995 (119.6 ± 5.4 mg /dl vs 149.1 ± 4.2; p < 0.05) as well as insulin requirements (3.2 ± 0.8 U vs 13.3 ± 1.9; p < 0.01) for the 180 min postprandial period. Similarly, glucagon level was reduced 30 min postprandially (24 ± 6 pg / ml vs 59 ± 24; p < 0.05) and so GH level only 180 min after lunch (p < 0.05). The premeal injection of SMS decreases postprandial glycemic excursions and the corresponding insulin requirement. The action of SMS 201–995 may be mainly mediated by the suppression of postprandial glucagon peak.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Gerich J.E., Schultz T.A., Lewis S.B., Karam J.H. Clinical evaluation of somatostatin as a potential adjunct to insulin in the management of diabetes mellitus. Diabetologia 13: 537, 1977.
Del Guercio M.G., Di Natale B., Gargantini L., Garlaschi C., Chiumello G. Effect of somatostatin on blood sugar, plasma growth hormone and glucagon levels in diabetic children. Diabetes 27: 300, 1978.
Christensen S.E., Hansen A.P., Weeke J., Lundbaek K. 24-hour studies of the effects of somatostatin on the levels of plasma growth hormone, glucagon and glucose in normal subjects and juvenile diabetics. Diabetes 27: 300, 1978.
Gerich J.E., Lorenzi M., Schneider V., Karam J.H., Rivier J., Guillemin R., Forsham P.H. Effects of somatostatin on plasma glucose and glucagon levels in human diabetes mellitus. N. Engl. J. Med. 291: 544, 1974.
Gerich J.E. Somatostatin and diabetes. Am. J. Med. 70: 619, 1981
Christensen S.E., Hansen A.P., Lundbaeck K. Somatostatin in maturity-onset diabetes. Diabetes 27: 1013, 1978.
Wahren J., Felig P. Influence of somatostatin on carbohydrate disposal and absorption in diabetes mellitus. Lancet ii: 1213, 1976.
Dimitriadis G., Tessari P., Gerich J. Effects of a long-acting somatostatin analogue on postprandial hyperglycemia in insulin-dependent diabetes mellitus. Metabolism 32: 987, 1983.
Candrina R., Giustina G. Effect of a new long-acting somatostatin analogue (SMS 201–995) on glycemic and hormonal profiles in insulin-treated type II diabetic patients. J. Endocrinol. Invest. 11: 501, 1988.
Williams G., Ball J.A., Burrin J.M., Joplin G.F., Bloom S.R. Effective and lasting growth-hormone suppression in active acromegaly with oral administration of somatostatin analogue SMS 201–995. Lancet ii: 774, 1986.
Wood S.M., Kraenzlin M.E., Adrian T.E., Bloom S.R. Treatment of patients with pancreatic endocrine tumours using a new long-acting somatostatin analogue, symptomatic and peptide response. Gut 26: 438, 1985.
Raskin F., Unger R.H. Hyperglucagonemia and its suppression. Importance in the metabolic control of the diabetes. N. Engl. J. Med. 299: 433, 1978.
Gomez-Pan A., Rodriguez-Arnao M.D., Del Pozo E. Advances in somatostatin research. In: Del Pozo E., Flueckiger F. (Eds.), Dopamine and neuroendocrine active substances. Academic Press, London, 1984, p. 223.
Spinas G., Bock A., Keller U. Reduced postprandial hyperglycemia after subcutaneous injection of a somatostatin analogue (SMS 201–995) in insulin-dependent diabetes mellitus. Diabetes Care 8: 429, 1985.
Serrano Rios M., Navascues I., Saban J., Ordonez A., Sevilla F., Del Pozo E. Somatostatin analog SMS 201–995 and insulin needs in insulin-dependent diabetic patients studied by means of an artificial pancreas. J. Clin. Endocrinol. Metab. 63: 1071, 1986
Del Pozo E., Neufeld M., Schluter K., Tortosa F., Klarenbach P., Bieder E., Wendel L., Neuesch E., Marbach P., Cramer H., Kerp L. Endocrine profile of a long-acting somatostatin derivative SMS 201–995. Study in normal volunteers following subcutaneous administration. Acta Endocrinol. (Kbh.) 111: 433, 1986.
Gerich J., Lorenzi M., Bier D., Tsalikian E., Schneider V., Karam J., Forsham P.H. Studies involving administration of exogenous hormone during suppression of endogenous hormone secretion with somatostatin. J. Clin. Invest. 57: 875, 1976.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nosari, I., Lepore, G., Querci, F. et al. Effects of a somatostatin derivative (SMS 201–995) on postprandial hyperglycemia in insulin-dependent diabetics studied by means of a closed-loop device. J Endocrinol Invest 12, 413–417 (1989). https://doi.org/10.1007/BF03350715
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03350715